Translational and Clinical Pharmacology, published by KSCPT, is an esteemed journal that serves as a vital source of knowledge in the field of pharmacology, particularly focusing on the translational aspects that bridge laboratory research and clinical applications. Established in 2014, this journal aims to disseminate high-quality research and reviews pertaining to drug development, therapeutics, and the underlying mechanisms of action in the medical realm. With an ISSN of 2289-0882 and an E-ISSN of 2383-5427, it holds a significant position with a Q3 ranking in the pharmacology category as of 2023, emphasizing its role in advancing scientific understanding within this crucial discipline. While it operates as a traditional subscription-based journal, its output remains accessible through various academic platforms, contributing to the global discourse in pharmacology. Researchers, professionals, and students will find value in its insightful articles and comprehensive studies, underscoring the journal’s commitment to enhancing pharmacological knowledge and practice.

Expert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

Kidney Cancer, published by IOS PRESS, is an esteemed open-access journal dedicated to advancing knowledge in the field of nephrology and oncology. Since its inception in 2017, this journal has provided a dynamic platform for researchers, practitioners, and students to disseminate their findings and discuss innovative approaches to kidney cancer treatment and research. With an ongoing commitment to fostering collaboration and sharing critical insights, Kidney Cancer aims to bridge gaps in understanding and promote new methodologies in patient care. Despite its current ranking in the lower quartiles of its category, the journal is positioned to make significant contributions to the academic community by publishing high-quality, peer-reviewed articles that enhance the discourse in kidney cancer research. Furthermore, its open-access model ensures that valuable research is accessible to a global audience, supporting the urgent need for advancements in this critical area of health. Join the conversation and contribute to the growing body of knowledge in this vital field.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

CLINICAL DRUG INVESTIGATION is a prestigious journal dedicated to the fields of Medicine and Pharmacology, published by ADIS INT LTD in the United Kingdom. With an ISSN of 1173-2563 and an E-ISSN of 1179-1918, this journal has been a crucial contributor to the scientific community since its inception in 1995. Recognized for its significant impact, it holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, placing it firmly in the 70th percentile within its field. Researchers, professionals, and students alike benefit from its commitment to publishing innovative studies and comprehensive reviews that advance understanding and application of clinical drugs. Although it does not currently offer open access options, its rigorous peer-review process ensures the integrity and quality of published articles. The journal's scope encompasses a wide range of topics related to drug investigation, making it an essential resource for anyone involved in medical research and pharmacological practice.